文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

伤口内万古霉素粉末预防成人脊柱侧凸手术手术部位感染的有效性与安全性(Vanco-SSIASS):一项前瞻性、随机对照、评估者盲法、开放标签、多中心试验的研究方案

The efficacy and safety of intrawound vancomycin powder to prevent surgical site infection in adult scoliosis surgery (Vanco-SSIASS): study protocol for a prospective, randomized controlled, assessor‑blinded, open‑label, multicenter trial.
PubMed 文献 · Trials · 2025-08-05

该研究方案拟在中国3所大学附属医学中心招募264例成人脊柱侧凸畸形(ASD)矫形手术患者,随机分为标准围手术期抗SSI治疗对照组(n=132)与加用伤口内万古霉素粉末1000 mg喷洒干预组(n=132),旨在验证其预防手术部位感染的有效性与安全性。

要点

  • 成人脊柱侧凸矫形术后手术部位感染(SSI)受关注,伤口内万古霉素粉末预防SSI的疗效与安全性仍存争议。
  • 该方案为前瞻性、随机对照、评估者盲法、开放标签、多中心试验,计划纳入264例ASD手术患者。
  • 干预组在标准围手术期抗SSI治疗基础上,于矫形手术中向手术部位喷洒注射1000 mg万古霉素。

核心结论

  • 目前尚无随机对照试验探讨伤口内万古霉素粉末预防成人脊柱侧凸手术手术部位感染的有效性与安全性,该试验旨在填补这一空白并指导成人脊柱畸形矫形手术的围手术期抗感染临床用药。

研究设计与样本

  • 该研究为多中心随机对照试验的研究方案,计划从中国3所大学附属医学中心的骨科住院患者中招募符合条件的成人脊柱侧凸畸形患者264例。
  • 采用区组随机化方法将患者随机分配至对照组(n=132)或干预组(n=132)。

主要发现

  • 对照组接受标准围手术期抗手术部位感染治疗;干预组在矫形手术中向手术部位喷洒注射1000 mg万古霉素,并接受标准围手术期抗手术部位感染治疗。

关键数值与推荐

  • 干预组万古霉素剂量为1000 mg,于矫形手术中喷洒注射于手术部位。
  • 试验注册号为ChiCTR2200059883,注册日期为2022年5月13日。

临床怎么用

  • 作者认为该随机对照试验将填补伤口内万古霉素粉末预防成人脊柱侧凸手术手术部位感染领域的空白,并指导成人脊柱畸形矫形手术的围手术期抗感染临床用药。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postoperative surgical site infections (SSIs) following adult scoliosis deformity (ASD) correction surgery are receiving more attention globally. Intrawound vancomycin powder in spinal surgical wounds has emerged as a promising strategy to prevent SSIs in recent years. However, the efficacy and safety of intrawound vancomycin powder in preventing SSIs following ASD correction surgery are still very controversial. This protocol describes a prospective, randomized controlled, multicenter clinical trial aimed at verifying vancomycin's efficacy and safety. METHODS: This is a study protocol for multicenter randomized controlled trial on efficacy and safety of intrawound vancomycin powder in preventing SSIs after ASD correction surgery. Eligible ASD patients (n = 264) will be recruited from the orthopedic inpatients of three university-affiliated medical centers in China. They will be randomly assigned to receive either standard perioperative anti-SSIs treatment (control group, n = 132), or 1000 mg vancomycin for spray injection on the surgical site during the correction surgery with standard perioperative anti-SSIs treatment (intervention group, n = 132) using a block randomization method. DISCUSSION: Up to now, there is no RCT (randomized controlled trial) to investigate the efficacy and safety of intrawound vancomycin powder to prevent surgical site infection in adult scoliosis surgery. We believe the RCT introduced in the article will fill the gap in this field and guide the perioperative anti-infection clinical medication for adult spinal deformity correction surgery. TRIAL REGISTRATION: ChiCTR2200059883. Registered on May 13, 2022. https://www.chictr.org.cn/showproj.html?proj=166621.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Han B, Hai Y, Yang Y, et al. The efficacy and safety of intrawound vancomycin powder to prevent surgical site infection in adult scoliosis surgery (Vanco-SSIASS): study protocol for a prospective, randomized controlled, assessor‑blinded, open‑label, multicenter trial. Trials. 2025. PMID: 40764586. doi:10.1186/s13063-025-09000-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。